文献速递眼底病与葡萄膜炎眼整形与眼眶

虹膜黑色素瘤经钯-103(103Pd)敷贴器近距离放射治疗后的消退模式

Regression Patterns of Iris Melanoma after Palladium-103 (103Pd) Plaque Brachytherapy.
PubMed 文献 · Ophthalmology · 2017-04-01

回顾性非随机干预性病例系列纳入50例虹膜原发恶性黑色素瘤患者,接受钯-103敷贴器近距离放射治疗。治疗后平均肿瘤厚度由1.4±0.6 mm降至0.9±0.2 mm,32例(64%)色素增加,内在血管中12例(63%)减少、7例(37%)完全消退。平均随访5.2年(范围0.5-17年),未见不可逆的视力限制性并发症。

要点

  • 虹膜黑色素瘤103Pd敷贴器治疗后最常见消退表现为内在肿瘤血管减少、色素增加和厚度降低。
  • 肿瘤厚度降低同步伴随超声内部反射性增高,42例低至中等内部反射性肿瘤中30例(60%)反射性增加。
  • 平均随访5.2年,未见放射性视网膜病变、黄斑病变或视神经病变的临床证据(0%)。

核心结论

  • 虹膜黑色素瘤103Pd敷贴器近距离放射治疗后最常见的消退相关表现为内在肿瘤血管减少、肿瘤色素增加和肿瘤厚度降低,并同步出现超声内部反射性增高。
  • 未观察到不可逆的视力限制性并发症。

研究设计与样本

  • 回顾性、非随机、干预性病例系列,共纳入50例虹膜原发恶性黑色素瘤患者,接受钯-103(103Pd)敷贴器近距离放射治疗。

主要发现

  • 病例系列平均年龄61.2±14.9岁,平均肿瘤厚度1.4±0.6 mm;按美国癌症联合委员会第八版虹膜黑色素瘤分期,T1a 21例(42%)、T1b 5例(10%)、T2a 24例(48%)。
  • 37例(74%)肿瘤为黑色素性,13例(26%)为无色素性;其中13例(26%)显示色素程度不一。
  • 近距离放射治疗后平均肿瘤厚度降至0.9±0.2 mm;色素增加32例(64%)、减少11例(22%)、不变6例(12%)。
  • 内在血管(n=19)中12例(63%)减少、7例(37%)完全消退;葡萄膜外翻减轻15例(43%);新出现瞳孔移位6例(12%)。
  • 高频超声显示42例(84%)低至中等内部反射性肿瘤中30例(60%)消退时内部反射性增加;虹膜基质萎缩26例(52%)、白内障进展或新发22例(44%)、新生血管性青光眼1例(2%)、角膜混浊0例;放射性视网膜病变、黄斑病变或视神经病变的临床证据0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the patterns of regression of iris melanoma after treatment with palladium-103 (103Pd) plaque brachytherapy. DESIGN: Retrospective, nonrandomized, interventional case series. PARTICIPANTS: Fifty patients with primary malignant melanoma of the iris. METHODS: Palladium-103 plaque brachytherapy. MAIN OUTCOME MEASURES: Changes in tumor size, pigmentation, and vascularity; incidence of iris neovascularization; and radiation-related complications. RESULTS: The mean age in the case series was 61.2±14.9 years. The mean tumor thickness was 1.4±0.6 mm. According to the American Joint Committee on Cancer, eighth edition, staging criteria for iris melanoma, 21 tumors (42%) were T1a, 5 tumors (10%) were T1b, and 24 tumors (48%) were T2a. The tumor was melanotic in 37 cases (74%) and amelanotic in 13 cases (26%); of these, 13 tumors (26%) showed variable pigmentation. After brachytherapy, mean tumor thickness decreased to 0.9±0.2 mm. Pigmentation increased in 32 tumors (64%), decreased in 11 tumors (22%), and was unchanged in 6 tumors (12%). For intrinsic vascularity (n = 19), 12 tumors (63%) showed decrease and 7 tumors (37%) showed complete resolution. Appearance of ectropion uveae showed diminution in 15 tumors (43%); newly present corectopia was observed in 6 patients (12%). On high-frequency ultrasound imaging, of the 42 tumors (84%) with low to moderate internal reflectivity, 30 tumors (60%) showed an increase in internal reflectivity on regression. Iris stromal atrophy was noted in 26 patients (52%), progression or new-onset cataract was noted in 22 patients (44%), neovascular glaucoma was noted in 1 patient (2%), and there were no cases of corneal opacity. There was no clinical evidence (0%) of radiation-induced retinopathy, maculopathy, or optic neuropathy. Mean follow-up in this series was 5.2 years (range, 0.5-17 years). CONCLUSIONS: The most common findings related to iris melanoma regression after 103Pd plaque brachytherapy included decreased intrinsic tumor vascularity, increased tumor pigmentation, and decreased tumor thickness with synchronous increase in internal ultrasonographic reflectivity. No irreversible sight-limiting complications were noted.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Chaugule SS, Finger PT. Regression Patterns of Iris Melanoma after Palladium-103 (103Pd) Plaque Brachytherapy. Ophthalmology. 2017. PMID: 28377036. doi:10.1016/j.ophtha.2017.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。